BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation https://ir.ataibeckley.com/news-rel...ates-rapid-and-durable-antidepressant-effects A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression https://journals.sagepub.com/doi/10.1177/02698811261420087
BPL-003 Nasal Spray Shows Quick and Enduring Effect in Treatment-Resistant Depression https://www.psychiatrictimes.com/vi...ring-effect-in-treatment-resistant-depression
Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles. https://www.psychologytoday.com/us/...er-battle-healing-the-invisible-wounds-of-war
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst https://ir.ataibeckley.com/news-rel...-trillion-crsp-index-and-sp-benchmark-indices
GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans https://www.marijuanamoment.net/gop...hedelics-research-and-treatment-for-veterans/
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? https://finance.yahoo.com/sectors/h...ibeckley-inc-atai-looking-sell-181120202.html
Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants https://www.science.org/doi/10.1126/sciadv.aeb3034 This paper is not about discovering new psychedelics. It is about controlling how they are made. The researchers produced DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT in a plant system by rebuilding the full biosynthetic pathway. The implication is on the production side, which is where this becomes relevant for companies like $DFTX, $ATAI, and $CMPS if they are positioned anywhere along the supply or formulation chain. A lot of these compounds today still rely on complex synthesis or extraction workflows. This approach shifts production toward programmable biosynthesis. That means more consistent batches, tighter purity control, and likely a lower cost per gram at scale. As these companies move through FDA pathways, manufacturing becomes critical. Cost of goods and consistency directly impact margins, scalability, and pricing. It is not just about proving the therapy works. It is about producing it reliably at pharmaceutical grade. The takeaway here is infrastructure. Lower production costs, better control, and more flexibility in compound design all strengthen the long term commercial case for companies working to bring these therapies to market.
